| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Niga-ichigoside F1 targets multiple pathways: it activates Nrf2 and inhibits the NF-κB pathway. It has anti-inflammatory effects by modulating oxidative stress and inhibiting pro-inflammatory cytokines. It also shows β-glucosidase and anti-acetylcholinesterase inhibitory activities.
|
|---|---|
| ln Vitro |
In HepG2 cells treated with free fatty acid (FFA), niga-ichigoside F1 (2.5, 5, 10, 20 μM; for 24 hours) reduces lipid accumulation in a dose-dependent manner. The viability of cells is unaffected by niga-ichigoside F1[1]. In Con, Niga-ichigoside F1 (20 μM), FFA (1 mM), and Niga-ichigoside F1 + FFA treated Nrf2-silenced cells, there is a decrease in both nuclear and cytoplasmic Nrf2 expressions[1].
In vitro, Niga-ichigoside F1 shows anti-inflammatory, gastroprotective, and cytotoxic effects. It exhibits inhibition zones on β-glucosidase and anti-acetylcholinesterase assays. It can induce apoptosis in tumor cells. It has antioxidant activity. |
| ln Vivo |
In four-week-old male C57BL/6J mice, niga-ichigoside F1 (40 mg/kg; oral gavage; for 12 weeks) reduces hepatic steatosis, potentially through a significant interaction with a high-fat diet (HFD) to control lipid metabolism genes (e.g., Srebp1c, Acc1, Fasn, Scd1, Cpt1a, and Fabp5)[1].
In vivo, Niga-ichigoside F1 (40 mg/kg; oral gavage; for 12 weeks) alleviates hepatic steatosis induced by high-fat diet in male mice. It activates Nrf2 and improves high-fat diet-induced hepatic steatosis. It inhibits the NF-κB pathway to alleviate DSS-induced ulcerative colitis. |
| Enzyme Assay |
Cell-free assays for Niga-ichigoside F1: β-glucosidase inhibition is measured using p-nitrophenyl-β-D-glucopyranoside as substrate, monitoring absorbance at 405 nm. Anti-acetylcholinesterase activity is assessed using Ellman's method. Antioxidant activity is measured using DPPH and ABTS assays. Nrf2 activation is assessed using ARE-luciferase reporter assays.
|
| Cell Assay |
Cellular assays for Niga-ichigoside F1: inflammatory cells (e.g., macrophages) are treated with the compound at concentrations of 0.1-100 µM for 1-24 hours, then stimulated with LPS or DSS. Pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) is measured by ELISA. Nrf2 nuclear translocation and NF-κB activation are assessed by immunofluorescence or Western blot. Cell viability is measured by MTT assay.
|
| Animal Protocol |
In vivo animal studies for Niga-ichigoside F1: high-fat diet-induced hepatic steatosis model in male mice: mice are fed a high-fat diet and treated with Niga-ichigoside F1 at 40 mg/kg orally for 12 weeks. Liver histology, lipid content, and Nrf2 activation are assessed. DSS-induced ulcerative colitis model: mice are treated with DSS and Niga-ichigoside F1, and disease severity, inflammatory markers, and NF-κB pathway activity are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Niga-ichigoside F1: as a triterpenoid saponin with a large molecular weight (666.9), it may have poor oral bioavailability. However, oral administration at 40 mg/kg shows in vivo efficacy, suggesting some degree of absorption. It is likely metabolized by intestinal flora and liver enzymes. Further PK studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicity of Niga-ichigoside F1: comprehensive toxicity data are limited. As a saponin, it may have hemolytic activity and gastrointestinal effects at high doses. However, oral administration at 40 mg/kg for 12 weeks was tolerated. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
19α-Hydroxyasiatic acid-28-O-β-D-glucopyranoside is a triterpenoid saponin composed of 19α-hydroxyasiatic acid linked to a β-D-glucopyranoside residue at position 28 via a glycosidic bond. It has been isolated from the leaves of Rosa laevigata. It is a plant metabolite. It is a triterpenoid saponin, a pentacyclic triterpenoid, a monosaccharide derivative, a β-D-glucopyranoside, and a tetraol. Functionally, it is related to 19α-hydroxyasiatic acid. It is derived from the hydride of arbutane. Niga-ichigoside F1 has been reported in Rosa laevigata, Rubus ellipticus var. obcordatus, and other organisms with relevant data.
Niga-ichigoside F1 is a research compound with potential applications in inflammatory diseases, hepatic steatosis, and cancer research. It is available as a reference standard for pharmacological studies. Its mechanism involves Nrf2 activation and NF-κB inhibition. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C36H58O11
|
|---|---|
| Molecular Weight |
666.84
|
| Exact Mass |
666.397
|
| CAS # |
95262-48-9
|
| PubChem CID |
16118969
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
775.0±60.0 °C at 760 mmHg
|
| Flash Point |
234.7±26.4 °C
|
| Vapour Pressure |
0.0±6.0 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
3.84
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
47
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
C([C@]12CC[C@@H](C)[C@](O)(C)[C@H]1C1=CC[C@@H]3[C@]4(C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]4CC[C@@]3(C)[C@@]1(CC2)C)C)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
|
| InChi Key |
WKKBYJLXSKPKSC-JVJIQXRHSA-N
|
| InChi Code |
InChI=1S/C36H58O11/c1-18-9-12-36(30(44)47-29-26(42)25(41)24(40)21(16-37)46-29)14-13-33(4)19(27(36)35(18,6)45)7-8-23-31(2)15-20(39)28(43)32(3,17-38)22(31)10-11-34(23,33)5/h7,18,20-29,37-43,45H,8-17H2,1-6H3/t18-,20-,21-,22-,23-,24-,25+,26-,27-,28+,29+,31+,32+,33-,34-,35-,36+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-1,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4996 mL | 7.4981 mL | 14.9961 mL | |
| 5 mM | 0.2999 mL | 1.4996 mL | 2.9992 mL | |
| 10 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
